Every Form 4 that Heartflow, Inc. (HTFL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HTFL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HTFL filings page.
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported option exercises and share sales in HTFL stock. On February 12, 2026, he exercised multiple stock options, converting them into common shares at exercise prices of $2.22 and $8.33 per share.
On the same date, he then sold 65,153 shares of common stock in open-market transactions at a weighted average price of $24.4883 per share, under a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, he held 76,034 shares directly, with additional indirect holdings reported in several family and personal trusts.
HeartFlow, Inc. Chief Accounting Officer and VP Marie L. Jones reported routine equity compensation and related tax withholding transactions. On February 6, 2026, she received 37,795 stock options with an exercise price of $27.74 per share, and 21,629 restricted stock units that vest quarterly over four years, starting from that date.
The filing also shows 94 shares of common stock were withheld by HeartFlow to cover income tax obligations from previously granted RSUs that vested, at a price of $27.74 per share. After these transactions, she directly owns 31,650 shares of common stock and 37,795 stock options.
Heartflow, Inc. CEO John C.M. Farquhar reported multiple equity transactions. On February 6, 2026, he was granted 183,850 restricted stock units at no cost, vesting in equal quarterly installments over four years starting on that date. The same day, 1,541 shares of common stock were withheld by the company to cover taxes tied to previously reported RSU vesting.
Also on February 6, 2026, he received a stock option for 321,259 shares at an exercise price of $27.74 per share, vesting in equal monthly installments over four years. On February 10, 2026, he sold 22,562 shares of common stock at a weighted average price of $27.46 under a Rule 10b5-1 trading plan, and reported owning 591,656 common shares and 321,259 options directly after these transactions.
HeartFlow, Inc.'s Chief Medical Officer, Campbell Rogers, reported new equity awards and related share activity. On February 6, 2026, he received a stock option covering 94,488 shares of common stock with a $27.74 exercise price, vesting monthly over four years starting from the vesting commencement date.
On the same date, he was granted 54,073 restricted stock units, which vest in 16 equal quarterly installments beginning February 6, 2026, subject to continued service. The filing also shows 515 shares of common stock withheld at $27.74 per share to cover tax obligations upon RSU vesting, and reports additional indirect common stock holdings through several trusts.
Heartflow, Inc. Chief Financial Officer Verghese Vikram received new equity awards and had shares withheld for taxes. On February 6, 2026, he was granted a stock option for 119,685 shares of common stock at an exercise price of $27.74 per share, vesting in 1/48 increments monthly from the vesting commencement date.
He also received 68,493 restricted stock units that begin vesting on February 6, 2026, with 1/16 of the RSUs vesting on each quarterly anniversary, contingent on continued service. In connection with the vesting and net settlement of previously reported RSUs, 542 shares of common stock were retained by Heartflow to satisfy income tax withholding obligations. Following these transactions, he directly beneficially owned 212,863 shares of common stock and 119,685 stock options.
Heartflow, Inc. director Julie A. Cullivan reported a planned stock sale. On February 5, 2026, she sold 8,000 shares of Common Stock of Heartflow at $27.32 per share, in an open-market transaction.
The filing states this trade was carried out under a pre-arranged Rule 10b5-1 trading plan that she adopted on September 12, 2025. After the sale, she continued to hold 36,413 shares of Heartflow common stock in direct ownership.
BCLS Fund III Investments, LP, a Bain Capital Life Sciences affiliated fund and 10% owner of Heartflow, Inc., reported a sale of 2,000,000 shares of Heartflow common stock on February 4, 2026 at $28.05 per share. After this transaction, BCLS Fund III Investments indirectly held 10,448,158 shares of Heartflow common stock. Related Bain Capital Life Sciences entities may be deemed to share voting and dispositive power over these securities and each disclaims beneficial ownership except to the extent of its pecuniary interest.
Heartflow, Inc. director Mr. Lightcap reported buying 40,000 shares of Heartflow common stock on 12/16/2025 in an open market purchase at a weighted average price of $26.342 per share. After this transaction, he holds 40,000 shares directly. The filing also lists additional indirect beneficial ownership through affiliated investment entities, including 4,615,542 shares held by HCPCIV 1, LLC, 833,075 shares held by HealthCor Partners Fund II, L.P., and 1,248,939 shares held by HealthCor Partners Fund, L.P., for which he is a controlling member and disclaims beneficial ownership beyond his economic interest.
HeartFlow, Inc. (HTFL) disclosed a routine insider transaction by its Chief Executive Officer and Director on 11/07/2025. The filing reports 1,339 shares of common stock reflected as a code F transaction at $32.56 per share, representing shares retained by the issuer to satisfy income tax withholding upon the vesting and net settlement of previously reported RSUs.
Following this administrative withholding event, the reporting person beneficially owns 431,909 shares, held directly.
HeartFlow, Inc. (HTFL) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/07/2025, the officer had 471 shares of common stock withheld/disposed at $32.56 under transaction code F, which reflects shares retained by the company to satisfy tax withholding upon the vesting and net settlement of previously reported RSUs. Following this event, the officer beneficially owns 144,912 shares directly.
Heartflow, Inc. filed a Form 4 reporting a tax-related share withholding from an RSU vesting. On 11/07/2025, 81 shares of common stock were withheld by the issuer at $32.56 per share under transaction code F.
The reporting person is an officer (Chief Accounting Officer, VP) and now directly holds 10,115 shares following the transaction. Code F reflects shares retained to satisfy income tax withholding obligations on previously reported RSUs, rather than an open-market sale.